Hematology Practice Questions

Q: Which of the following is NOT a feature of POEMS Syndrome?

Multiple sclerosis. ***Multiple sclerosis*** - **Multiple sclerosis** is a chronic, demyelinating disease of the central nervous system and is not part of the diagnostic criteria or typical manifestations of POEMS syndrome [1]. - POEMS syndrome is a **paraneoplastic syndrome** associated with plasma cell dyscrasia, not an autoimmune CNS disorder [2]. *Polyneuropathy* - **Polyneuropathy** is a core and defining feature of POEMS syndrome, typically a demyelinating sensorimotor type [2]. - The "P" in POEMS stands for **Polyneuropathy**. *Organomegaly* - **Organomegaly**, particularly hepatomegaly, splenomegaly, or lymphadenopathy, is a common feature of POEMS syndrome. - The "O" in POEMS stands for **Organomegaly**. *Endocrinopathy* - **Endocrinopathy**, such as hypogonadism, diabetes mellitus, or hypothyroidism, is frequently observed in POEMS syndrome [2]. - The "E" in POEMS stands for **Endocrinopathy**.

Q: Which of the following is commonly seen in Polycythemia Vera?

Thrombosis. ***Spontaneous severe infection*** - In Polycythemia Vera, there is usually an **increased red blood cell mass** leading to complications like thrombosis, rather than a predisposition to severe infections. - Severe infections are not a typical feature, as the condition usually maintains **functional immunity** despite hyperviscosity. *Thrombosis* - Individuals with Polycythemia Vera have increased blood viscosity that results in a higher risk of **thrombosis**, which is a common complication [1]. - Events like **deep vein thrombosis (DVT)** or **cerebral venous sinus thrombosis** are often observed due to altered hemodynamics. *Hyperuricemia* - Hyperuricemia occurs due to increased cell turnover and breakdown of red cells in Polycythemia Vera, leading to elevated **uric acid levels** [1]. - Patients may experience **gout attacks** as a consequence of this elevated uric acid [1]. *Prone for acute leukemia* - While there is an increased risk of transformation to myeloid neoplasms, the risk for **acute leukemia** is not directly attributed to Polycythemia Vera in most cases. - It is more related to myelofibrosis or secondary conditions developing over time rather than a direct association.

Q: What are the key characteristics of Evans syndrome?

Autoimmune hemolytic anemia and immune thrombocytopenia. ***Autoimmune hemolytic anemia and immune thrombocytopenia*** - **Evans syndrome** is defined by the simultaneous or sequential occurrence of **autoimmune hemolytic anemia (AIHA)** and **immune thrombocytopenia (ITP)** [1], [2]. - Both conditions involve the immune system mistakenly attacking and destroying **red blood cells** and **platelets**, respectively [1], [2]. *Low lymphocyte and red blood cell counts* - While **red blood cell counts** are low in Evans syndrome due to AIHA, **lymphocyte counts** are not a defining characteristic; they can vary. - This option does not fully capture the dual autoimmune destruction of red blood cells and platelets specific to Evans syndrome. *High platelet and lymphocyte counts* - **Platelet counts** are **low** in Evans syndrome due to ITP, not high. - **Lymphocyte counts** are not characteristically high; a high count might suggest other conditions like leukemias or lymphomas. *A reduction in all blood cell types* - A reduction in all (red blood cells, white blood cells, and platelets) is known as **pancytopenia**, which is not the defining feature of Evans syndrome. - Evans syndrome specifically involves the destruction of **red blood cells** and **platelets**, but not necessarily all white blood cell types.

Q: What is the recommended time frame for completing a blood transfusion after initiation?

1-4 hours. ***1-4 hours*** - This timeframe is recommended to **minimize the risk of bacterial growth** in the blood product, as bacteria can multiply quickly at room temperature. - Completing the transfusion within 4 hours also reduces the likelihood of **red blood cell degeneration** and loss of efficacy. *3-6 hours* - This period extends beyond the recommended maximum of 4 hours, increasing the risk of **bacterial proliferation** in the blood product. - Prolonged infusion times can also lead to a **decrease in the viability and function** of transfused cells. *4-8 hours* - Transfusing over 4-8 hours significantly elevates the risk of **bacterial contamination** and potential septic reactions. - The extended duration compromises the **quality and safety** of the blood product. *8-12 hours* - This timeframe is unacceptably long for a blood transfusion, posing a **critical risk of severe bacterial growth** and infection. - Blood products should not be administered beyond 4 hours due to the rapid decline in **cell integrity and increased adverse reaction potential**.

Q: Which of the following does not synthesize von Willebrand factor?

Hepatocytes. ***Hepatocytes*** - Von Willebrand factor (vWF) is primarily synthesized by **endothelial cells** and **megakaryocytes** [1], not hepatocytes. - Hepatocytes are responsible for synthesizing other proteins like **clotting factors**, but not vWF. *Megakaryoctyes* - Megakaryocytes play a crucial role in the synthesis of **platelet-derived factors**, including von Willebrand factor (vWF) [1]. - They release vWF into the bloodstream, facilitating platelet adhesion, especially in vascular injury sites. *None* - The option implies all listed cell types synthesize vWF, which is incorrect, as **only endothelial cells and megakaryocytes** produce it [1]. - Suggests a misunderstanding of the synthesis of coagulation-related factors, as hepatocytes do not produce vWF. *Endothelial cells* - Endothelial cells are the primary source of **von Willebrand factor** [1], releasing it to assist in platelet aggregation and clotting. - They are essential for the body's response to vascular injury, facilitating hemostasis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 669-670.

Q: Response to iron therapy in iron deficiency anemia is denoted by?

Reticulocytosis. Reticulocytosis - Reticulocytosis is one of the earliest signs of a positive response to iron therapy in iron deficiency anemia, occurring within 5-10 days. - It signifies that the bone marrow is effectively producing new red blood cells after iron supplementation. Restoration of enzymes - While iron is a crucial component of many enzymes (e.g., catalase, cytochrome oxidase), its restoration takes time and is not the primary immediate indicator of therapeutic response. - Clinical improvement and other hematological parameters precede the full restoration of enzyme function. Increase in hemoglobin - An increase in hemoglobin is a definitive sign of successful treatment, but it occurs later than reticulocytosis, typically visible after several weeks to months of therapy. - Hemoglobin levels rise as the new, iron-sufficient red blood cells fully mature and replace the older, iron-deficient ones. Increase in iron binding capacity - In iron deficiency anemia, total iron-binding capacity (TIBC) is typically increased due to more transferrin being available to bind iron [1]. - Successful iron therapy would lead to a decrease in TIBC as transferrin sites become saturated with iron, not an increase.

Q: Cryoprecipitate is useful in which of the following conditions?

Afibrinogenemia. ***Afibrinogenemia*** - Cryoprecipitate is rich in **fibrinogen**, factor VIII, factor XIII, von Willebrand factor, and fibronectin. It is the only blood product with a substantial concentration of fibrinogen. - **Afibrinogenemia** (or hypofibrinogenemia) is a condition characterized by low or absent levels of fibrinogen, a critical clotting factor that cryoprecipitate replaces effectively. *Hemophilia A* - Hemophilia A is a deficiency of **Factor VIII**. While cryoprecipitate contains factor VIII, **recombinant Factor VIII concentrates** are the preferred treatment due to better safety (reduced risk of viral transmission) and more precise dosing [1]. - Cryoprecipitate was historically used for Hemophilia A before the availability of safer, more specific factor concentrates [2]. *Thrombosthenia* - Thrombasthenia is a platelet function disorder characterized by defective **glycoprotein IIb/IIIa receptors** on platelets, leading to impaired platelet aggregation. - Cryoprecipitate does not contain platelets or factors that directly correct platelet function, making **platelet transfusions** the treatment of choice for severe bleeding in thrombasthenia. *Warfarin reversal* - Warfarin reversal is primarily achieved using **Vitamin K**, which restores levels of functional clotting factors II, VII, IX, and X. - For rapid reversal in emergencies, **prothrombin complex concentrate (PCC)** is preferred because it contains high concentrations of these vitamin K-dependent factors, addressing the primary deficiency caused by warfarin [1].

Q: Which of the following statements about Sickle Cell Anemia is FALSE?

Patients usually present before the age of 6 months. ***Patients usually present before the age of 6 months*** - This statement is **FALSE** because sickle cell anemia patients typically become symptomatic **after 6 months of age**, when **fetal hemoglobin (HbF)** levels decline. - **HbF is protective** against sickling, so symptoms like **dactylitis** and **splenic sequestration** usually manifest once HbF is replaced by HbS. *There is a positive correlation between HBS and polymerization of HBS* - This statement is **TRUE** as higher levels of **hemoglobin S (HbS)** lead to increased **polymerization** and sickling of red blood cells. - The **polymerization of deoxygenated HbS** is the primary pathophysiologic mechanism causing vaso-occlusive crises and hemolysis. *Recurrent infections is the most common cause of death* - This statement is **TRUE**, particularly in children with sickle cell anemia due to **functional asplenia** from repeated splenic infarctions. - **Splenic dysfunction** impairs clearance of **encapsulated bacteria**, increasing risk of severe infections like **pneumococcal sepsis** and **meningitis**. *Patients require frequent blood transfusions* - This statement is **TRUE** as **chronic transfusion therapy** is a standard treatment for managing severe complications and preventing stroke. - Transfusions help **suppress HbS production**, dilute existing sickle cells, and reduce the frequency of **vaso-occlusive crises**.

Question 1

Which of the following is NOT a feature of POEMS Syndrome?

Accepted Answer

Multiple sclerosis

Answer

Organomegaly

Answer

Endocrinopathy

Answer

Polyneuropathy

Question 2

Which of the following is commonly seen in Polycythemia Vera?

Accepted Answer

Thrombosis

Answer

Hyperuricemia

Answer

Prone for acute leukemia

Answer

Spontaneous severe infection

Question 3

What are the key characteristics of Evans syndrome?

Accepted Answer

Autoimmune hemolytic anemia and immune thrombocytopenia

Answer

Low lymphocyte and red blood cell counts

Answer

High platelet and lymphocyte counts

Answer

A reduction in all blood cell types

Question 4

34 week primigravida punjabi khatri comes with history of consanguineous marriage, with history of repeated blood transfusion to her sibling since 8 months of age. The first diagnostic test is -

Accepted Answer

Hb electrophoresis

Answer

HPLC

Answer

Bone marrow

Answer

Blood smear

Question 5

What is the recommended time frame for completing a blood transfusion after initiation?

Accepted Answer

1-4 hours

Answer

3-6 hours

Answer

4-8 hours

Answer

8-12 hours

Question 6

Which of the following does not synthesize von Willebrand factor?

Accepted Answer

Hepatocytes

Answer

Endothelial cells

Answer

Megakaryocytes

Answer

None of the options

Question 7

Response to iron therapy in iron deficiency anemia is denoted by?

Accepted Answer

Reticulocytosis

Answer

Increase in hemoglobin

Answer

Restoration of enzymes

Answer

Increase in iron binding capacity

Question 8

Cryoprecipitate is useful in which of the following conditions?

Accepted Answer

Afibrinogenemia

Answer

Hemophilia A

Answer

Thrombosthenia

Answer

Warfarin reversal

Question 9

Thrombotic thrombocytopenic purpura is a syndrome characterized by which of the following?

Accepted Answer

Thrombocytopenia, anemia, neurological abnormalities, progressive renal failure and fever

Answer

Thrombocytopenia, anemia, neurological abnormalities, progressive hepatic failure and fever

Answer

Thrombocytopenia, normal anemia, neurological abnormalities, progressive renal failure and fever

Answer

Thrombocytopenia, anemia, no neurological abnormalities, progressive renal failure and fever

Question 10

Which of the following statements about Sickle Cell Anemia is FALSE?

Accepted Answer

Patients usually present before the age of 6 months

Answer

There is a positive correlation between HBS and polymerization of HBS

Answer

Recurrent infections is the most common cause of death

Answer

Patients require frequent blood transfusions

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?